Soligenix (LTS:0A6I) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0A6I Soligenix Inc LTS:0A6I
41 GF Score
Price $0.36
GF Value $3.61
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Soligenix Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

LTS:0A6I
41GF Score
Soligenix Inc LTS:0A6I
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Soligenix (LTS:0A6I) Overvalued in 2026?

Based on GuruFocus' analysis, Soligenix stock appears to be undervalued. The current stock price of $0.36 is trading 90% below its estimated GF Value™ of $3.61. GuruFocus considers Soligenix to be Possible Value Trap.

Key valuation signals for LTS:0A6I:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: $3.61 vs. price of $0.36 (90% below fair value)
  • GF Score™: 41/100 with 1 warning sign

No single metric tells the full story. See the LTS:0A6I stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Soligenix Business Description

Other Exchanges SNGX:USA
Address 29 Emmons Drive, Suite B-10, Princeton, NJ, USA, 08540
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
41GF Score

Get the complete analysis for LTS:0A6I

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.36
Price
$3.61
GF Value